“Long Term Outcomes for Basal Cell Carcinoma Treated with Vismodegib Extended Alternate Day Dosing”, J of Skin, vol. 3, no. 2, pp. 150–151, Mar. 2019, doi: 10.25251/skin.3.2.32.